Focus Financial Network Inc. Has $5.82 Million Stock Position in Eli Lilly and Company $LLY

Key Points

• Focus Financial Network Inc. reduced its holdings in Eli Lilly and Company by 13.3%, selling 1,145 shares and leaving them with a total of 7,460 shares valued at approximately $5.8 million.
• CEO David A. Ricks purchased 1,632 shares for about $1.05 million, marking a 0.30% increase in his ownership, while Director Gabrielle Sulzberger increased her stake by 4.52% with a purchase of 117 shares.
• Eli Lilly reported better-than-expected quarterly earnings of $6.31 EPS, exceeding estimates by $0.72, and its revenue rose to $15.56 billion, up 37.6% from the previous year.

Focus Financial Network Inc. lowered its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 13.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,460 shares of the company's stock after selling 1,145 shares during the quarter. Focus Financial Network Inc.'s holdings in Eli Lilly and Company were worth $5,816,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. WestEnd Advisors LLC increased its position in Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after acquiring an additional 21 shares during the period. Wealth Preservation Advisors LLC acquired a new stake in Eli Lilly and Company during the first quarter worth $27,000. Citizens National Bank Trust Department boosted its stake in Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after buying an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. acquired a new stake in Eli Lilly and Company during the first quarter worth $40,000. Finally, TD Capital Management LLC boosted its stake in Eli Lilly and Company by 129.2% during the first quarter. TD Capital Management LLC now owns 55 shares of the company's stock worth $46,000 after buying an additional 31 shares in the last quarter. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Trading Down 1.2%

NYSE:LLY traded down $9.41 on Friday, hitting $753.52. 7,319,147 shares of the stock were exchanged, compared to its average volume of 3,181,974. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The stock has a market capitalization of $713.17 billion, a price-to-earnings ratio of 49.25, a P/E/G ratio of 1.05 and a beta of 0.47. The company's 50-day moving average price is $738.37 and its 200 day moving average price is $770.79. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $939.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company's revenue was up 37.6% on a year-over-year basis. During the same period in the prior year, the business posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 10th. Investors of record on Friday, August 15th were given a $1.50 dividend. The ex-dividend date was Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. Eli Lilly and Company's payout ratio is currently 39.22%.

Insiders Place Their Bets

In other Eli Lilly and Company news, Director Gabrielle Sulzberger acquired 117 shares of the firm's stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the transaction, the director owned 2,703 shares of the company's stock, valued at $1,733,109.54. This trade represents a 4.52% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director J Erik Fyrwald acquired 1,565 shares of the firm's stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the transaction, the director directly owned 74,578 shares in the company, valued at $47,903,686.74. This trade represents a 2.14% increase in their position. The disclosure for this purchase can be found here. Insiders acquired 4,514 shares of company stock worth $2,894,841 in the last three months. 0.13% of the stock is owned by corporate insiders.

Analyst Ratings Changes

LLY has been the topic of a number of recent research reports. UBS Group decreased their price target on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Deutsche Bank Aktiengesellschaft reduced their target price on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a research note on Monday, August 11th. DZ Bank upgraded shares of Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 14th. JPMorgan Chase & Co. reduced their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating on the stock in a research note on Tuesday, September 16th. Finally, Cantor Fitzgerald reduced their target price on shares of Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 13th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of "Moderate Buy" and a consensus price target of $939.61.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.